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Simple Summary: Head and neck squamous cell carcinoma are epithelial tumors with a very poor
prognosis. They are also in high need of new targeted and immune-based therapeutics to limit tumor
recurrence and improve long-term survival. The poor prognosis of patients with head and neck
tumors is usually associated with histological features associated with poor di↵erentiation and high
proliferative activity found in their tumor biopsies. Therefore, it is of paramount importance to
identify vulnerabilities associated with such pathobiological programs. In this work, the authors
utilize a stem cell-like program linked to the deregulated activity of VAV2, a protein frequently
overexpressed in this type of tumors, to identify new therapeutic targets that can discriminate tumors
from healthy cells. The authors also show that this gene expression program can be used to stratify
patients according to long-term prognosis.
Abstract: We have recently shown that VAV2, a guanosine nucleotide exchange factor that catalyzes
the stimulation step of RHO GTPases, is involved in a stem cell-like (SCL) regenerative proliferation
program that is important for the development and subsequent maintenance of the tumorigenesis
of both cutaneous (cSCC) and head and neck squamous cell carcinomas (hnSCC). In line with this,
we have observed that the levels of the VAV2 mRNA and VAV2-regulated gene signatures are associated
with poor prognosis in the case of human papillomavirus-negative hnSCC patients. These results
suggest that the SCL program elicited by VAV2 in those cells can harbor therapeutically actionable
downstream targets. We have addressed this issue using a combination of both in silico and wet-lab
approaches. Here, we show that the VAV2-regulated SCL program does harbor a number of cell cycle-
and signaling-related kinases that are essential for the viability of undi↵erentiated keratinocytes and
hnSCC patient-derived cells endowed with high levels of VAV2 activity. Our results also show that
the VAV2-regulated SCL gene signature is associated with poor hnSCC patient prognosis. Collectively,
these data underscore the critical role of this VAV2-regulated SCL program for the viability of both
preneoplastic and fully transformed keratinocytes.
Keywords: VAV2; VAV family; Rac1; RhoA; GTPases; skin; head and neck; keratinocytes; cancer;
oncogenes; signaling; regenerative proliferation; stem cells
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1. Introduction
One of the hallmarks of cancer cells is their ability to hijack molecular programs that are usually
restricted to progenitor and stem cells [1]. This provides cancers with unrestrained growth potential,
plasticity, adaptability to environmental changes, and survival mechanisms against many of the current
therapies [1]. In line with this, the enrichment of stem cell-like features in tumors is frequently one
of the leading parameters associated with worse prognosis. This is clearly exemplified in squamous
cell carcinomas (SCCs), in which the presence of such features correlate with poor patient survival [2].
As a consequence, there is a growing interest in the blockade of the stem cell-like features of tumor
cells [3]. Nevertheless, doing so without negatively a↵ecting the physiological function of healthy
stem cells remains a major concern when considering clinical applications [1]. As it occurs in the
case of other cancer-associated pathobiological programs, the eventual success of such therapies
would rely on the degree of addiction that tumor cells might develop for the targeted processes when
compared to the healthy counterparts [4]. In this context, the identification of biomarkers able to
predict tumor cell dependency towards specific stem cell-associated molecular pathways holds great
translational potential.
Recent sequencing and molecular taxonomy studies have revealed that the activation of
RHO GTPase-regulated biological processes is a common signaling feature for most SCCs [5,6].
Consistent with this, we have recently found that VAV2, a guanosine nucleotide exchange factor (GEF)
that promotes the activation of RHO GTPases during cell signaling [7–10], plays a pivotal role in
this process. Thus, its chronic activation in mice leads to epithelial hyperplasia in the skin, palate,
and other head and neck areas. The same phenotype is observed when tested in three-dimensional (3D)
organotypic cultures. Although not enough for triggering cell transformation per se, we also observed
that its constitutive activation in the skin epidermis creates a pro-tumorigenic niche that, upon the
generation of further genetic lesions, favors enhanced tumor formation and progression in mice [11].
Conversely, the use of catalytically hypomorphic Vav2 knock-in mice has revealed that the enzymatic
activity of this GEF is essential for skin SCC initiation, promotion and progression [12]. Perhaps more
importantly, we have observed that the elimination of endogenous VAV2 eliminates the tumorigenic
potential of hnSCC patient-derived cells and standard hnSCC cancer cell lines using both orthotopic
xenotransplants in vivo and 3D organotypic cultures [11]. Further supporting the relevance of this GEF
for this type of tumors, we have found that the levels of the VAV2 mRNA and VAV2-regulated gene
signatures correlate with poor prognosis in the case of human papilloma virus-negative hnSCC patients [11].
It is as yet unclear whether the foregoing data can be exploited pharmacologically to treat cSCC and
hnSCC patients given the di culties traditionally found in the development of high-a nity inhibitors
for most RHO GEFs [6]. An alternative avenue to achieve this goal is to find therapeutic vulnerabilities
among the VAV2-regulated gene expression programs present in epithelial cells. One of them is a
SCL program associated with regenerative proliferation and extensive cell undi↵erentiation driven by
the VAV2-mediated activation of the transcriptional factors c-MYC and YAP/TAZ. Consistent with
this, we have found that c-MYC and YAP/TEAD inhibitors lead to reduced proliferation and extensive
di↵erentiation of keratinocytes ectopically expressing an active version of VAV2, respectively [11].
To explore this possibility, we implemented here a multifaceted approach aimed at the identification
of therapeutic Achilles’ heels in the VAV2-regulated SCL program. This has resulted in the identification
of a number of cell cycle- and signaling-regulated protein kinases that are essential for the viability of
undi↵erentiated cells associated with upregulated VAV2 signaling. Interestingly, we have found that
the inhibition of these kinases is not detrimental for normal epithelial cells at the concentrations used
in our experiments. Finally, we demonstrate that the VAV2-driven SCL program is associated with
hnSCC patient survival. Collectively, this work indicates that the VAV2-regulated SCL programs can
be used both as therapeutic and diagnostic tools for cSCC and hnSCC.
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2. Methods
2.1. Ethics Statement
Animal work was done according to protocols approved by the Bioethics committee of Salamanca
University and the Castilla y León autonomous government (Approval Number 315).
2.2. In Silico Analyses
Vav2Onc mouse skin expression microarray data were obtained from the GSE124019 dataset
generated in a previous work [11]. Signal intensity values were obtained from CEL files after applying
the Robust Multichip Average (RMA) function from the ‘a↵y’ package for background adjustment,
quantile normalization and summarization [13]. Gene Set Enrichment Analyses (GSEA) were carried
out with the described gene sets using gene set permutations (n= 1000) for the assessment of significance
and signal-to-noise metric for ranking genes [14]. The stemness-related gene sets used in GSEA analyses
include those for epidermal progenitor cells [15], SCC initiating cells [16], and normal embryonic stem
cells [17–19].
Functional annotation was performed using Metascape (accessed on September 2019) [20].
Known functional interactions among relevant genes were obtained through the String tool [21].
Cytoscape open-source software was used to perform network data integration and visualization [22].
For the discovery of transcription factor binding motifs in the promoters of the co-regulated genes,
the iRegulon open-source software was used [23]. A collection of 9713 position weight matrices (PWMs)
was applied to analyze 10 kb centered around the TSS. With a maximum false discovery rate (FDR) on
motif similarity below 0.001, we performed motif detection, track discovery, motif-to-factor mapping
and target detection.
Prediction of drug vulnerability and gene dependency were performed using LINCS [24] and
DepMap [25], respectively. ssGSEA [14,26] against the GSE30784 dataset [27] was used to evaluate the
enrichment of the Vav2Onc-driven stemness signature in SCC tumors as indicated elsewhere [11].
Overall survival analyses were performed through Kaplan–Meier estimates according to the
enrichment of the Vav2Onc-regulated stemness signature using the GSE41613 dataset [28]. The median
of the enrichment distribution for the signature was used to establish the low and high expression
groups and, subsequently, the Mantel–Cox test was applied to statistically validate the di↵erences
between the survival distributions.
2.3. Primary Mouse Keratinocytes
Primary keratinocytes were isolated from newborn Vav2Onc/Onc and control animals [29] as
described elsewhere [30]. To this end, the skin were extracted from mice of the indicated genotypes,
treated with dispase (250 U/mL; Roche, Basel, Switzerland; Catalog No. 04942078001) overnight
at 4  C. The next day, the epidermis was separated from the dermis and treated with Accutase
(CELLnTEC, Bern, Switzerland; Catalog No. CnT-Accutase-100) for 30 min at 37  C to extract the
keratinocytes. Cultures were them kept in CnT07 medium (CELLnTEC, Catalog No. CnT-07) on type I
collagen-coated plates (BD Biosciences, San Jose, CA, USA; Catalog No. 356400).
2.4. Human Keratinocyte Cell Lines
Immortalized, primary neonatal human keratinocytes (KerCT cells) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA; Catalog No. CRL-4048). These cells
have been immortalized by ectopically expressing human TERT and CDK4. KerCT cell derivatives
ectopically expressing mouse Vav2Onc were described before [11]. All these cells were cultured in
KGM-Gold medium (Lonza, Basel, Switzerland; Catalog No. 00192060).
SCC-25 cells, obtained from Dr. Salvador A. Benitah (Institute for Research in Biomedicine,
Barcelona, Spain), were cultured in KSFM medium (Thermo Fisher Scientific, Waltham, MA, USA;
Catalog No. 17005-042) supplemented with 25 µg/mL bovine pituitary extract (Thermo Fisher Scientific,
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Catalog No. 17005-042) and 0.5 ng/mL human epidermal growth factor (Thermo Fisher Scientific,
Catalog No. 17005-042).
hnSCC (tongue-located) patient-derived cells were provided by Dr. Salvador A. Benitah [31].
VdH15 cells were cultured in KSFM medium supplemented with 25 µg/mL bovine pituitary extract
and 0.5 ng/mL human epidermal growth factor (Thermo Fisher Scientific, Catalog No. 17005-042).
VdH01 cells were cultured in a FAD+ medium that was composed of three parts of DMEM
(Gibco, Waltham, MA, USA; Catalog No. 21969) and one part of Ham’s F12 medium (Thermo Fisher Scientific,
Catalog No. 11765054) supplemented with 10% fetal bovine serum (Gibco, Catalog No. 10270106),
1.8 ⇥ 10 4 M adenine (Sigma-Aldrich, Saint Louis, MO, USA Catalog No. A2786-5G), 0.5 µg/mL
hydrocortisone (Sigma-Aldrich, Saint Louis, MO, USA; Catalog No. H4001-1G), 5 µg/mL insulin
(Thermo Fisher Scientific, Catalog No. 12585014), 10 ng/mL EGF (PreproTech, Rocky Hill, NJ, USA;
Catalog No. AF-100-15), 10–10 M cholera toxin (Sigma-Aldrich, Catalog No. C8052-5MG), and 2 mM
L-glutamine (Gibco, Catalog No. 25030024).
2.5. Three-Dimensional Organotypic Cultures
Exponentially growing keratinocytes maintained in CnT-Prime medium (CELLnTEC, Catalog No. CnT-PR)
were detached using Accutase, centrifuged at 300⇥ g for 5 min at room temperature, and counted.
A total of 2 ⇥ 105 cells were then seeded onto polycarbonate inserts (Thermo Fisher Scientific,
Catalog No. 140620) and cultured for two days in CnT-Prime medium. Upon confluency, the medium
was changed to 3D-Barrier (CELLnTEC, Catalog No. CnT-PR-3D) and the air-lift performed according
to the manufacturer’s instructions. 3D cultures were maintained for 12 days with three medium changes
per week. When indicated, the inhibitors and corresponding vehicles were applied in the sixth day after
carrying out the airlift and refreshed with the medium changes indicated above. Inhibitors used included
Alisertib (Selleckchem, Munich, Germany; Catalog No. S1133), XL413 (Selleckchem, Catalog No. S7547),
AZD7762 (Selleckchem, Catalog No. S1532), and BI2536 (Selleckchem, Catalog No. S1109) (10 nM each).
Concentrations of inhibitors were selected based on the induction of minor e↵ect in the organotypic
structures formed by control cells.
2.6. Histological Studies
Three-dimensional cultures were fixed in 4% paraformaldehyde, para n embedded, cut in 2–3 µm
thick sections, and stained with hematoxylin-eosin. Images were captured using an Olympus BX51
microscope coupled to an Olympus DP70 digital camera. The thickness of the epidermal layer and/or total
skin thickness were measured in vertical cross-sections using the ImageJ software (NIH, Bethesda, MD, USA) [32].
2.7. Statistics
The number of biological replicates (n), the type of statistical tests performed, and the statistical
significance are indicated for each experiment either in the figure legends or in the main text.
Data normality and equality of variances were analyzed with Shapiro-Wilk and Bartlett’s tests,
respectively. Parametric distributions were analyzed using Student’s t-tests (when comparing two
experimental groups) or ANOVA followed by Tukey’s HSD tests (when comparing more than two
experimental groups with every other group). In all cases, values were considered significant when
p  0.05. Data obtained are given as the mean ± SEM.
3. Results
3.1. Discovery of Pharmacological Targets in the Vav2Onc-Driven SCL Keratinocyte Program
In order to understand the role of upregulated VAV2 signaling in epithelial cells, we recently
utilized a catalytic gain-of-function knock-in mouse strain that expresses a mutant version of the mouse
Vav2 protein (N-terminal 1–186 deletion, referred to hereafter as Vav2Onc). This mutant protein exhibits
constitutive GEF activity due to the removal of most N-terminal autoinhibitory domains that maintain
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the inactive state of VAV family proteins in the absence of tyrosine phosphorylation [7,8,10]. Due to this,
the biological activity of this active version must reflect the output of the wild-type protein under optimal
tyrosine phosphorylation conditions according to the current VAV family regulatory model [7,8,10].
Importantly, Vav2Onc is expressed from the endogenous locus and, therefore, exhibits pattern and
levels of expression in tissues identical to the endogenous wild-type counterpart [12]. These mice
develop extensive hyperplasia in the epidermal linings of both the skin and head and neck areas [11].
Microarray and functional studies revealed that this phenotype develops as the consequence of the
activation of a regenerative proliferation program that contains molecular features typical of an
undi↵erentiated, SCL state [11]. In agreement with these previous studies, Gene Set Enrichment
Analyses (GSEA) revealed that the Vav2Onc-regulated transcriptome present in mouse skin epithelial
cells harbors gene signatures previously found in epidermal progenitor cells, SCC initiating cells,
and normal embryonic stem cells (Figure 1A,C,E). This SCL state is highly aberrant, since it does show
any statistically significant enrichment in gene signatures corresponding to the transcriptomes of hair
follicle stem cells.
The functional annotation of these Vav2Onc-regulated SCL gene programs revealed quite similar
functional features. Thus, the three signatures were enriched in proliferation-associated genes such as
those involved in cell cycle regulation, chromosome condensation, DNA replication, spindle assembly,
mitosis, cell division or anabolic processes (Figure 1B,D,F). In the case of the SCC initiating cell-like
signature, this enrichment also includes genes linked to inflammatory, cell death, and histone
methylation responses (Figure 1D). Finally, the normal embryonic stem-like signature specifically
harbors genes linked to both RNA metabolism and translation (Figure 1F).
We next investigated whether this stem cell-like programs were associated with some
“gene addiction” that could be exploited pharmacologically. In order to find the most promising targets,
we first decided to analyze the genes that were redundantly present in at least two of the foregoing SCL
transcriptional programs triggered by Vav2Onc. We found 91 genes (18% of the total number of genes)
that fulfilled this a priori criterion (Figure 2A). This set of genes, referred hereafter as the Vav2Onc
common SCL signature (CSS), encodes proteins mainly involved in cell cycle progression such as
cyclin family members, protein kinases, helicases, topoisomerases, nucleases, kinesins, and variety of
transcription factors (Figure 2B–D).
Analyses of enriched transcription factor binding sites suggest that the expression of the Vav2Onc
CSS is under the control of the transcriptional factors E2F, NFY and, to a lesser extent, Htatip2,
Mnt and Rfx (Figure 2E) [33–37].
We next used the library of integrated network-based cellular signatures to predict potential chemical
perturbagen vulnerabilities derived from the Vav2Onc CSS [24]. In keeping with the microarray and
functional annotation data, we found that the highest-ranking group of drugs predicted to be effective
against this Vav2Onc-driven transcriptional program includes inhibitors for cell cycle-associated proteins,
receptor protein tyrosine kinases (RTKs), phosphatidylinositol 3-kinase (PI3K), and mitogen-activated
protein kinases (MAPKs) (Figure 2F). These data are also consistent with previous studies indicating that
the elimination of VAV proteins in the skin leads to defects in both Ras–ERK and PI3K–Akt signaling [30].
We next selected a number of potential pharmacological targets within the Vav2Onc-driven CSS using
two a priori criteria: (i) Clear association with tumor cell fitness according to the Cancer Dependency
Map Project [25] (Figure 2G). (ii) Availability of commercial inhibitors for them. This strategy led us to
focus our analysis on five candidate targets: aurora kinases A (Aurka) and B (Aurkb), the cell division
cycle 7-related protein kinase (Cdc7), the checkpoint kinase 1 (Chek1) and the polo-like kinase 1 (Plk1)
(Figure 2C,D,G).




Figure 1. VAV2 controls a stem cell-like transcriptional program in keratinocytes. (A,C,E) Gene Set
Enrichment Analyses (GSEA) of the indicated gene sets (top) in the Vav2Onc-dependent skin
transcriptome. The normalized enrichment scores (NES) and false discovery rate q-values (FDR q-val)
are indicated within each graph. Positive enrichments are indicated with upward-pointing arrows.
The expression heatmap for the top 10 leading-edge probesets is also included. (B,D,F) Functional
networks depicting the most enriched functional terms in the leading edge of the GSEA shown in
A,C,E. Node size is proportional to the significance of the enrichment. Related functional terms are
linked by edges.
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Figure 2. Identification of druggable Vav2Onc-induced cell stemness targets. (A) Venn diagram
showing the overlap among the di↵erent Vav2Onc-induced stemness signatures according to the
GSEA shown in Figure 1A,C,E. (B) Main functional categories encoded by the Vav2Onc common SCL
signature (CSS). (C) List of genes comprising the Vav2Onc CSS. Those that were selected as candidate
druggable targets are highlighted in color. (D) Protein interaction network of the genes comprising
the Vav2Onc CSS. Those that were selected as candidate druggable targets are highlighted in dark
color. (E) Enriched transcription factor binding sites in the promoter regions of the genes belonging to
the Vav2Onc CSS. The normalized enrichment score (NES) and percentage of hits for each transcription
factor binding site are also indicated. (F) Sector graph showing the top drug categories enriched against
the Vav2Onc CSS according to the LINCS project. The number of circles is proportional to the enrichment
Z score. (G) DepMap analysis of the dependency of tumor cell line panels in CRISPR (blue) and RNAi
(purple) databases for the indicated genes (top). Strong dependency is indicated as common essential (CE).
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3.2. Keratinocytes with High Vav2 Activity are Highly Dependent on Aurora, Cdc7, Check1 and Plk1
Kinase Activities
To validate the targets identified in Figure 2, we next tested the e↵ect of a collection of pharmacologic
inhibitors for aurora kinases a and b (Alisertib), Cdc7 (XL413), Chek1 (AZD7762) and Plk1 (BI2536)
(Figure 3A). All the selected compounds show high specificity towards the targets, with the exception of
AZD7762 that can also block the related Chek2 kinase [38–41] (Figure 3A). These inhibitors were tested
in 3D organotypic cultures of keratinocytes to mimic what happens in the context of a fully formed
epithelium. In addition, this strategy allowed us to specifically address the e↵ect of the inhibitors in
the basal, suprabasal and fully di↵erentiated keratinocyte layers present in this cell culture-generated
epithelium. Importantly, we chose concentrations of each drug (10 nM) that did not cause in pilot
experiments significant interference with the growth and di↵erentiation of control cells under 3D
culture conditions (Figure 3B,C). With this strategy, we expected to unveil vulnerabilities specifically
linked to the gain-of-function events elicited by Vav2Onc in those cells.
Under these culture conditions, the primary keratinocytes isolated from the skin of newborn
Vav2Onc/Onc mice form a hyperplastic epithelium (Figure 3B,C), thus recapitulating the phenotype
observed in the skin and head and neck areas of Vav2Onc/Onc mice [11]. The addition of each of those
inhibitors to the 3D cultures triggers massive cell death in the suprabasal layers of the epithelium
formed by Vav2Onc/Onc keratinocytes (Figure 3B,C). However, the basal layers display a normal
structure, forming a thin but viable epithelium (Figure 3B,C). The e↵ect observed is specific for
Vav2Onc-expressing suprabasal cells, because the inhibitors do not elicit any over e↵ect on the epithelial
structures formed by the keratinocytes obtained from the wild-type mice (Figure 3B,C).
To extend these findings to the human context, we next tested the e↵ect of those drugs in 3D
organotypic cultures of human keratinocytes (Ker-CT cells). These cells have been immortalized,
but not transformed, by the ectopic expression of both human telomerase reverse transcriptase and
cyclin-dependent kinase 4 [42]. As in the case of keratinocytes from newborn Vav2Onc/Onc mice,
we found that the human keratinocytes ectopically expressing the constitutively active mouse Vav2Onc
protein could also generate a highly hyperplastic epithelium (Figure 3D,E). The addition of Alisertib
and XL413 blocks this hyperplastic phenotype, leading to the formation of epithelia with a thickness
similar to than found in control cells (Figure 3D,E). The treatments with AZD7762 and BI2536 elicit a
more dramatic e↵ect, leading to the formation of aberrant epithelial structures that were even thinner
than those generated by control cells (Figure 3D,E). The reason for the disparity in the e↵ects of the
inhibitors on mouse and human keratinocytes is unknown. It can be due to the much higher levels
of expression of Vav2Onc in the latter cells or, alternatively, to the fact that these cells also ectopically
express the cyclin-dependent kinase 4.
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cultures using the primary mouse keratinocytes of the indicated genotypes (top) upon treatment
with th indicated drugs (left). Scale bar, 10 µm (n = 3). WT, wild-type. Vav2Onc; Vav2Onc/Onc mice.
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3.3. The Viability of hnSCC Cells is Highly Dependent on Vav2Onc-Regulated Actionable Targets
We have recently shown that endogenous wild-type human VAV2, which is overexpressed in many
hnSCC samples and hnSCC patient-derived cells [11], is critical for the tumorigenic and metastatic
properties of hnSCC cancer cell lines (SSC-25) and hnSCC patient-derived cells (VdH15, VdH01)
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when tested in orthotopic xenotransplant experiments in immunocompromised mice. This phenotype
is associated with reduced and increased levels of cell proliferation and terminal di↵erentiation,
respectively [11]. When tested in 3D organotypic cultures, the VAV2 knockdown cells exhibit the
same proliferative and di↵erentiation defects when compared to the respective parental SSC-25,
VdH15 and VdH01 counterparts [11]. We observed that the addition of Alisertib, AZD7762 and BI2536
to those cells results in a significant destruction of the 3D cultures generated by each of those cell
models (Figure 4A and data not shown). This indicates that the viability of these three types of hnSCC
cells is highly dependent on the activity of aurora, Chek1, and Plk1 kinases. By contrast, we found
that the XL413 elicited a milder e↵ect that resulted in the reduced ability of these cells to form highly
enlarged and deorganized tissues in 3D culture conditions (Figure 4A–C). Collectively, these results
indicate that the activity of aurora, Cdc7, Check, and Plk1 are critical Achilles’ heels for the viability of
keratinocytes and hnSCCs containing high levels of endogenous VAV2 activity. By contrast, the activity
of each of those kinases is less relevant for naïve keratinocytes, even those that, as is the case of
Vav2Onc/Onc basal keratinocytes, normally exhibit high levels of proliferative activity.
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